Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2023)
14 slides from Biotron's shareholder meeting presentation, Nov 22, 2023
Slide 1: Presentation to Annual General Meeting (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2023 The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000 (14 pages by email) For personal use only Dear Madam, PRESENTATION
Slide 2: Chairman's Address to the AGM
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2023 CHAIRMAN’S ADDRESS TO THE AGM My Fellow Shareholders During the past 12 months, Biotron completed, successfully, three clinical trial
Slide 3: Annual General Meeting
> S ANNUAL GENERAL D MEETING 7 Cc oO D © ASX:BIT ra) 22 November 2023 LL Biotron
Slide 4: Forward Looking Statements
Forward Looking Statements > “Chis presentation may contain forward-looking statements with respect to the financial Condition, results and business achievements/performance of Biotron Limited (ACN 086 399 944) and certain of the plans and objectives of its management. These statements are -statemen
Slide 5: Industry-leading experts focused on transformative viral treatments
Industry-leading experts focused on transformative viral treatments y Experienced Board & Management team with pharma, finance and VC backgrounds Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large international markets For pers
Slide 6: Near-term value creation milestones anticipated in late 2023
Near-term value creation milestones anticipated in late 2023 O1 Headline results from 3 human Phase 2 trials expected in coming weeks * Two HIV-1 Phase 2 trials anda SARS-CoV-2/COVID-19 Phase 2 trial + Allthree trials have been completed Le. all patients have been recruited and completed dosing with
Slide 7: Portfolio of Clinical & Preclinical Assets
Portfolio of Clinical & Preclinical Assets RESEARCH DEVELOPMEN IND ENABLING/ LEAD PHASE 1 2 PHASE 3 OPTIMISATION PRECLINICAL firmer] renee [macs | For personal use only INDICATION HIV-1 HIV-1 COVID-19 COVID-19 HBV Dengue, Influenza & others COMPOUND BIT225 Next gen BIT225 Next gen Lead optimisation
Slide 8: Recent Milestones & Achievements
For personal use only Recent Milestones & Achievements Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies Completed enrolment of Phase 2 COVID-19 clinical trial Based on demonstration that B!T225 prevents development of COVID-19 disea
Slide 9: Why COVID?
Why COVID? =a =Be = For personal use only Vulnerable populations remain at risk Current drugs have limitations due to dosing, interactions with other meds, etc Long COVID is a growing issue, affecting ~65 million people Strong international focus on ensuring preparedness for future pandemics Need to
Slide 10: COVID-19 Clinical Program
COVID-19 Clinical Program In 2022 BIT's lead antiviral drug was shown to: + Prevent COVID-19 ° Reduce virus levels, and * Stop the cytokine storm in a relevant, robust, industry-recognised animal model of disease As BIT225 had been tested in humans for other viral diseases it could move quickly into
Slide 11: Why HIV-1?
Why HIV-1? globally livi HiVd deat from AIDS For personal use only Biotron The increased prevalence of HIV-1 infections, % of patients on treatment due to improved disease awareness and the need for treatments to improve quality of life are expected to drive market growth to over US$SOb by 2030 An e
Slide 12: HIV-1 Clinical Program
HIV-1 Clinical Program Two Phase 2 HIV-1 clinical trials recently completed at sites in Sydney, Australia & in Thailand Results expected in coming weeks These trials build on 9 previous clinical trials of BIT225 that established safety and potential benefits in patients with HIV-1 and Hepatitis C vi
Slide 13: BIT225 Opportunity Summary
BIT225 Opportunity Summary BIT225 is an important clinical asset o Previous positive clinical trial data have significantly de-risked the program === Clear clinical development program designed to demonstrate to regulators Cc and pharma how the drug may be used to O improve health outcomes in combin
Slide 14: Biotron Limited contact details
For personal use only Biotron BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329